Clinical trials: Immunity to COVID-19
Covid19
Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a
VBI-2902a and VBI-2905a are investigational vaccine candidates that use enveloped virus-like particle (eVLP) expression of a modified version of the SARS-CoV-2 spike (S) glycoprotein and are designed to induce neutralizing…
- Trial name
- NCT04773665
- Testing
- VBI-2902a, VBI-2905a
- Where
- 4 sites in Canada
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- VBI Vaccines Inc.
SARS-CoV 2
Immune Responses to COVID-19; Isolation of Neutralizing Antibodies for Therapeutics and Vaccine.
According to different projections, the COVID-19 outbreak currently happening in France and worldwide could result in millions of deaths in the absence of efficient therapies.
- Trial name
- AcNT-COVID19 (NCT04596098)
- Testing
- Blood sampling
- Where
- France
- Volunteers
- 55 people
- Sponsor
- University Hospital, Grenoble
SARS-CoV2 Infection Common Pathogens, Diabetes Mellitus, Type 1
Characterisation of the Immune Response to SARS-CoV-2 Infection / COVID-19 in Type 1 Diabetes
Emerging clinical details of the current SARS-CoV-2 pandemic have illustrated that there are multiple clinical presentations and outcomes of this viral infection.
- Trial name
- TIRID (NCT05171998)
- Testing
- venous blood sample
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cwm Taf University Health Board (NHS)
Covid19
Study to Reinforce Immunity (STRI) Phase 2 Clinical Trial
Protocol STRI12 - Study to Reinforce Immunity (STRI) - A Phase 2 Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of STRI Formula in Non-Hospitalized Participants with COVID-19 (the Study)
- Trial name
- NCT05046561
- Testing
- STRI Formula
- Where
- 13 sites in United States
- Volunteers
- 598 people
- Sponsor
- Eyecheck, Inc.
Covid19
ImmuneRACE - Immune Response Action to COVID-19 Events
ImmuneRACE is a study, which is designed to better understand the immune response to COVID-19. This is critically important because the immune system may be able to tell us important information about how our own bodies detect…
- Trial name
- NCT04494893
- Where
- United States
- Volunteers
- 808 people, healthy volunteers welcome
- Sponsor
- Adaptive Biotechnologies
COVID-19, Vaccine Reaction
Investigating COVID-19 Vaccine Immunity in Children in the Melbourne Infant Study of BCG for Allergy and Infection Reduction
The COSI BAIR trial will involve approximately 60 children, aged 5 to 8 years old, comprising a subset of participants from the Melbourne Infant Study BCG for Allergy and Infection Reduction (MIS BAIR) randomised controlled…
- Conditions
- COVID-19, Vaccine Reaction, Immunization; Infection
- Trial name
- COSI BAIR (NCT05168709)
- Testing
- Tozinameran
- Where
- Australia
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Murdoch Childrens Research Institute
Covid19
Prevalence of Thrombosis in COVID-Patients
Examination of the prevalence of thrombosis in COVID-patients, especially in an out-patient setting. Assessment by duplex sonography. If thrombosis is detected, we will correlate it with immunity status.
- Trial name
- NCT04615026
- Testing
- duplex sonography
- Where
- Germany
- Volunteers
- 525 people
- Sponsor
- University Hospital Augsburg
Core Body Temperature in Healthy Subjects, Immune Response to mRNA COVID-19 Vaccination
Fever Tracking Study
The aim of this study is to investigate the feasibility of continuous fever tracking of participants having fever symptoms in a home setting, using a core body temperature (CBT) sensor.
- Trial name
- NCT05475067
- Where
- Switzerland
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Covid19, SARS-CoV Infection
COVID-19 in Polish Ice Swimmers.
Ice swimming is an increasingly common phenomenon in Poland. It has been confirmed that it has a beneficial effect on health by increasing the natural non-specific immunity to infections.
- Conditions
- Covid19, SARS-CoV Infection, Resistance, Disease, Hypothermia
- Trial name
- ICE (NCT04817280)
- Testing
- Ice Swimming
- Where
- 3 sites in Poland
- Volunteers
- 2,534 people, healthy volunteers welcome
- Sponsor
- Wroclaw Medical University
Multiple Sclerosis
A Study to Assess COVID-19 Vaccination Immune Response in Multiple Sclerosis Patients Treated With Ofatumumab
This was a non-interventional, retrospective, observational cohort study involving the abstraction and review of pertinent data from medical records by participating physicians, who completed a customized electronic case report…
- Trial name
- NCT06460324
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals
COVID-19
Lymph Node Aspiration to Decipher the Immune Response of Beta-variant Recombinant Protein Booster Vaccine (VidPrevtyn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in Adults Previously Vaccinated With at Least 3 Doses of COVID-19 mRNA Vaccine.
In order to investigate whether a germinal center response occurs following vaccine boost and to characterize it based on the type of vaccine received, we aim to analyze Spike and/or RBD-specific germinal center B cells within…
- Trial name
- LymphoBOOST (NCT05951920)
- Testing
- Lymph node aspiration / Blood sampling
- Where
- France
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
SARS-CoV 2, COVID
Precision Immunology to Determine the Immune Response in Patients With COVID-19
To better understand the immune response to SARS-CoV-2 infection, we devised a precision immunology approach to systematically study the immune function of different patient cohorts
- Trial name
- NCT04360733
- Testing
- Blood draw
- Where
- Germany
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Bonn
Covid19, Cancer
Immune Response to the COVID-19 Vaccine
Explore the effects on immune response to include a potential third vaccine for the cancer cohort.
- Conditions
- Covid19, Cancer, Malignancy, Vaccine Response Impaired
- Trial name
- NCT04936997
- Testing
- SARS-COV2 Pfizer Vaccine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Arizona
Zinc Deficiency, Sars-CoV-2 Infection
Zinc Supplementation Impact in Acute COVID-19 Clinical Outcomes
Infections with SARS-CoV-2 result in a systemic disease with a variety of outcomes, from no symptoms to severe and diverse pathologies.
- Trial name
- MARZINC (NCT05778383)
- Testing
- Zinc Acetate
- Where
- Spain
- Volunteers
- 75 people
- Sponsor
- Parc de Salut Mar
Influenza, COVID-19
Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults After Vaccination
Background: Influenza (flu) vaccinations are required for all NIH staff members who have direct contact with patients. COVID-19 vaccines are recommended for persons 6 months of age and older.
- Trial name
- NCT04794829
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Heart Transplantation, COVID-19 Virus Infection
Covid-19 Vaccine Response in Heart Transplant Recipients
Clinical studies indicate a decrease in vaccine efficacy in certain immunocompromised populations (kidney transplant recipients, patients undergoing chemotherapy).
- Conditions
- Heart Transplantation, COVID-19 Virus Infection, COVID-19 Vaccine
- Trial name
- COVHEART (NCT05268679)
- Testing
- Biospecimen Collection, Questionnaire, Electronic Health Record Review
- Where
- France
- Volunteers
- 190 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Immunogenicity, Hematological Malignancies
Immunogenicity of Covid-19 Vaccination for Patients With Hematological Malignancies
Covid-19 is associated with a mortality rate of 33-37% in patients with hematological malignancies. At present, the anti-SARS-CoV-2 vaccination represents the most effective strategy for the prevention of Covid-19.
- Conditions
- Immunogenicity, Hematological Malignancies, Covid-19, Vaccine Response Impaired
- Trial name
- NCT04878822
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Ospedale di Circolo - Fondazione Macchi
SARS CoV 2 Infection
Phase II Study of AVX/COVID-12 Vaccine in Subjects With Prior SARS-CoV-2 Immunity Evidence
This is a Phase II study with single-blinded safety phase followed by double-blinded randomization, placebo-controlled, of administration of a single dose by two different administration routes (intramuscular route or intranasal…
- Trial name
- NCT05205746
- Testing
- Recombinant NDV Vectored Vaccine for SARS-CoV-2
- Where
- 4 sites in Mexico
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Laboratorio Avi-Mex, S.A. de C.V.
Immunity to COVID-19
Immunity After COVID-19 Vaccination
The purpose of the research is to evaluate new blood tests, which measure immunity to the COVID-19 coronavirus after vaccination. These tests will be used to measure T-cell and antibody immunity after COVID-19 vaccination.
- Trial name
- NCT04883164
- Testing
- Cellular and antibody response to spike antigens of SARS-CoV-2 in both groups in peripheral blood samples
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Plexision
SARS-CoV-2 Infection, Anti-SARS-CoV-2 Infection
Registry of Sustained Immunity to COVID-19 Among ESKD Patients
This is a multi-center, prospective registry study of subjects undergoing hemodialysis for treatment of end-stage renal disease in a DaVita center.
- Trial name
- RePAiR (NCT04495764)
- Where
- 12 sites in United States
- Volunteers
- 2,315 people
- Sponsor
- Davita Clinical Research